Cargando…
PREVALENCE OF POTENTIAL DRUG-DRUG INTERACTIONS WITH RITONAVIR-CONTAINING COVID-19 MEDICATIONS AMONG THE ADULT PATIENT POPULATION IN AUSTRALIA: ANALYSIS OF PHARMACEUTICAL BENEFITS SCHEME 10% SAMPLE (PBS10) CLAIMS
INTRO: Oral antiviral agents with differing modes of action are now available for the treatment of COVID-19. However, potentially life-threatening drug-drug interactions (DDIs) may occur if patients’ underlying co-morbidities are treated with medications that are contraindicated with ritonavir-conta...
Autores principales: | Cameron, C., Chen, W.-T., Tan, W.-H., Chen, Y., Lam, C., Igho-Osagie, E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Published by Elsevier Ltd.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10186947/ http://dx.doi.org/10.1016/j.ijid.2023.04.221 |
Ejemplares similares
-
Identifying incident cancer cases in dispensing claims: A validation study using Australia’s Repatriation Pharmaceutical Benefits Scheme (PBS) data
por: Daniels, B, et al.
Publicado: (2019) -
Drug Policy Down Under: Australia's Pharmaceutical Benefits Scheme
por: Duckett, Stephen J.
Publicado: (2004) -
Prevalence of potential drug-drug interactions with ritonavir-containing COVID-19 therapy
por: Igho-Osagie, Ebuwa, et al.
Publicado: (2023) -
Potential Cyp3a4-Mediated Drug-Drug Interactions with Ritonavir-Containing Medications in U.S. Patients with Diabetes or Cardiovascular Diseases: An Analysis of Nhanes Data
por: Igho-Osagie, Ebuwa, et al.
Publicado: (2022) -
Number of drugs provided by the Pharmaceutical Benefits Scheme and mortality and hospital utilization in Australia, 2002–2019
por: Lichtenberg, Frank R.
Publicado: (2023)